ArticleTranslational cancer research2026
Multi-cohort validation of
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint blockade (ICB) has transformed melanoma therapy, but predictive biomarkers remain suboptimal. Methods: We analyzed three independent cohorts: Memorial Sloan Kettering Cancer Center (MSK) (n=320, ICB-treated), The Cancer Genome Atlas (TCGA) (n=448, mixed treatments), and a combined ICB cohort (CS, n=436). Patients were categorized into four groups: co-mutation, Results: In ICB-treated cohorts (MSK and CS), only co-mutation consistently predicted superior OS, while single mutations showed no consistent benefit. Co-mutated tumors exhibited significantly higher TMB and neo-antigen loads, an immune-inflamed microenvironment with elevated M1 macrophages, reduced Tregs, and upregulation of programmed death-ligand 1 (PD-L1), CTLA-4, TIM-3, as well as enrichment of IFN-γ and IL6-JAK-STAT3 pathways. The combined risk score (co-mutation + TMB) predicted clinical benefit with an area under the curve (AUC) of 0.659. Patients with high-risk score (2 points) demonstrated significantly higher clinical benefit rates compared to low-risk score (0 points). Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.